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Abstract
Background: Numerous case–control studies have been performed to investigate the association between three
cyclooxygenase-2 (COX-2) polymorphisms (rs20417 (−765G > C), rs689466 (−1195G > A), and rs5275 (8473 T > C))
and the risk of head and neck squamous cell carcinoma (HNSCC). However, the results were inconsistent. Therefore,
we conducted this meta-analysis to investigate the association.
Methods: We searched in PubMed, Embase, and Web of Science up to January 20, 2015 (last updated on May 12,
2016). Two independent reviewers extracted the data. Odds ratios (ORs) with their 95 % confidence intervals (CIs)
were used to assess the association. All statistical analyses were performed using the Review Manager (RevMan)
5.2 software.
Results: Finally 8 case–control studies were included in this meta-analysis. For unadjusted data, an
association with increased risk was observed in three genetic models in COX-2 rs689466 polymorphism;
however, COX-2 rs5275 and rs20417 polymorphisms were not related to HNSCC risk in this study. The
pooled results from adjusted data all revealed non-significant association between these three polymorphisms
and risk of HNSCC. We also found a similar result in the subgroup analyses, based on both unadjusted data and
adjusted data.
Conclusion: Current results suggest that COX-2 rs689466, rs5275, and rs20417 polymorphisms are not associated
with HNSCC. Further large and well-designed studies are necessary to validate this association.
Keywords: COX-2 rs689466, COX-2 rs5275, COX-2 rs20417, Polymorphism, Head and neck squamous cell
carcinoma, Meta-analysis
Background
Head and neck squamous cell carcinoma (HNSCC) is
1 of the disease burdens worldwide affecting eating,
breathing, and appearance. Besides environmental
risk factors, such as tooth loss [1], alcohol consump-
tion [2], periodontal diseases [3], smoking [4], tooth
brushing [5], and human papillomavirus (HPV) [6],
genetic factors [7, 8] also play an significant role in
the onset and development of HNSCC. Many poly-
morphisms have been identified associated with risk
of HNSCC by meta-analyses, such as the hOGG1
Ser326Cys polymorphism [9], XRCC1 Arg194Trp
polymorphism [10], ERCC2 rs1799793 and rs13181
polymorphisms [11]; however, some polymorphisms
including XPD Asp312Asn polymorphism [12], TP53
codon 72 polymorphism [7], and VEGF gene poly-
morphisms [13] are not associated with HNSCC risk.
Particularly within the same gene, theXRCC1gene
for example, XRCC1 Arg194Trp polymorphism was
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associated with increased risk while Arg399Gln and
Arg280His polymorphisms were not [10].
The human cyclooxygenase-2 (COX-2), the key en-
zyme in the conversion of arachidonic acid to pros-
tatglandins, is located at chromosome 1q25.2-q25.3
and rs20417 (−765G > C), rs689466 (−1195G > A), and
rs5275 (8473 T > C) are the three commonly investi-
gated polymorphisms in the COX-2 gene [14, 15].
Now the association between COX-2 gene polymor-
phisms and risk of many cancers, such as hepatocel-
lular carcinoma [16], colorectal cancer [17], breast
cancer [18], prostate cancer [19], gastric cancer [20]
were investigated by meta-analyses. COX-2 has been
confirmed very low or no expression in normal hu-
man oral tissues, otherwise it was elevated in oral
precancerous lesions and over-expressed in oral squa-
mous cell carcinoma (OSCC) [21]. The elevated ex-
pression of COX-2 was presented to be correlated
with malignant transformation, advancing clinical
stage, and disease progression [22].
There are also many published studies that ex-
plored the association between COX-2 rs689466,
rs5275, and rs20417 polymorphisms and risk of HNSCC.
Unfortunately, the results of published studies were incon-
sistent and using a meta-analytic method to pool these re-
sults for obtaining a more precise result [23] is necessary.
In this meta-analysis, we extracted and combined crude
data and adjusted data.
Methods
We reported this meta-analysis according to the Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) statement [24] and ethical approval is
not necessary.
Eligibility criteria
Cohort studies or case–control studies evaluating the
risk of HNSCC in relation to COX-2 rs689466,
rs5275, and/or rs20417 polymorphisms were consid-
ered for eligibility if they also met the following cri-
teria: (1) the cancer was HNSCC, oral squamous cell
carcinoma (OSCC), or laryngeal squamous cell carcin-
oma (LSCC) confirmed using microscopic examin-
ation; (2) the frequency of genotype distribution,
adjusted odds ratios (ORs) and their 95 % confidence
intervals (CIs), or the data that can calculate them
Fig. 1 Study selection flowchart
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Table 1 Characteristics and unadjusted data of included studies





methodsSample size Genotype distribution
rs689466 (−1195G > A) GG GA AA
Chiang 2008 China (Asian) OSCC 368/441 80/114 187/235 101/92 Yes Mixed PCR-RFLP
Peters 2009 Netherlands (Caucasian) HNSCC 431/438 275/260 134/163 22/15 Yes Mixed PCR
Mittal 2010 India (Asian) OSCC 193/137 3/5 57/32 133/100 Yes Smokers PCR-RFLP
Chang 2013 China (Asian) HNSCC 313/295 93/90 146/148 74/57 Yes Mixed Taqman
Niu 2014 China (Asian) HNSCC 259/1035 61/222 126/542 72/271 Yes Mixed Taqman
OSCC 140/1035 44/222 80/542 25/271 Yes Mixed Taqman
LSCC 90/1035 17/222 46/542 27/271 Yes Mixed Taqman
rs5275 (8473 T > C) TT TC CC
Campa 2007 European (multicenter) HNSCC 553/711 252/313 237/321 44/77 Yes Mixed TaqMan
OSCC 252/711 113/313 117/321 22/77 Yes Mixed TaqMan
LSCC 281/711 139/313 120/321 22/77 Yes Mixed TaqMan
Mittal 2010 India (Asian) OSCC 135/59 74/24 53/34 8/1 No Smokers PCR-RFLP
Chang 2013 China (Asian) HNSCC 313/295 209/199 89/86 15/10 Yes Mixed Taqman
Niu 2014 China (Asian) HNSCC 258/1032 177/691 72/316 9/25 Yes Mixed Taqman
OSCC 168/1032 118/691 45/316 5/25 Yes Mixed Taqman
LSCC 90/1032 59/691 27/316 4/25 Yes Mixed Taqman
rs20417 (−765G > C) GG GC CC
Lin 2008 China (Asian) OSCC 297/280 193/107 104/173 0/0 Yes Mixed PCR–RFLP
Chiang 2008 China (Asian) OSCC 178/205 136/166 42/39 0/0 Yes Mixed PCR–RFLP
Peters 2009 Netherlands (Caucasian) HNSCC 428/433 321/321 99/99 8/13 Yes Mixed PCR
Mittal 2010 India (Asian) OSCC 176/96 92/41 78/49 6/6 Yes Smokers PCR–RFLP
Lakshmi 2012 India (Asian) OSCC 150/150 110/142 28/6 12/2 No Mixed PCR–RFLP











Table 2 Adjustment and adjusted data of included studies
Study Form of disease Reference OR (95 % CI) Adjustment
rs689466 (−1195G > A)
Peters 2009 HNSCC GG: 1.00 GA: 0.79 (0.58–1.07); age (continuous), sex, smoking (continuous, 5 levels),
and alcohol consumption (continuous, 3 levels)
AA: 1.24 (0.60–2.56)
Mittal 2010 OSCC GG: 1.00 GA: 3.07 (0.66–13.24); age, gender
AA: 2.22 (0.52–9.50)
G: 1.00 A: 1.03 (0.60–1.42)
Chang 2013 HNSCC GG: 1.00 GA: 0.86 (0.56–1.32); sex, age, education, cigarette smoking (pack-year categories),
betel quid chewing (pack-year categories), and alcohol
drinking (frequency)AA: 1.23 (0.72–2.09);
GA + AA: 0.96 (0.64–1.43);
G: 1.00 A: 1.08 (0.83–1.40)
Niu 2014 HNSCC GG: 1.00 GA:0.85 (0.60–1.21) age, sex, smoking status, and drinking status
AA: 1.01 (0.69–1.50)
GA + AA: 0.91 (0.65–1.26)
OSCC GG: 1.00 GA: 0.74 (0.49–1.11)
AA: 0.87 (0.55–1.39)
GA + AA:0.78 (0.53–1.14)
LSCC GG: 1.00 GA:1.16 (0.65–2.09)
AA:1.43 (0.75–2.75)
GA + AA:1.23 (0.71–2.15)
rs5275 (8473 T > C)
Campa 2007 HNSCC TT: 1.00 TC: 1.03 (0.82–1.28); age, sex, center, tobacco consumption (packyears),
and years of alcohol consumption
CC: 0.75 (0.51–1.10);
TC + CC: 0.97 (0.78–1.20)
OPSCC TT: 1.00 TC: 1.16 (0.86–1.58);
CC: 0.91 (0.53–1.54);
TC + CC: 1.11 (0.83–1.49)
LSCC TT: 1.00 TC: 0.88 (0.63–1.22);
CC: 0.60 (0.34–1.05);
TC + CC: 0.82 (0.60–1.12)
Mittal 2010 OSCC TT: 1.00 TC: 0.27 (0.03–2.26); age, gender
CC: 0.28 (0.03–2.33)
T: 1.00 C: 0.88 (0.55–1.40)
Chang 2013 HNSCC TT: 1.00 TC: 1.04 (0.69–1.56); sex, age, education, cigarette smoking (pack-year
categories), betel quid chewing (pack-year categories),
and alcohol drinking (frequency)CC: 1.89 (0.74–4.82);
TC + CC: 1.12 (0.75–1.65)
Niu 2014 HNSCC TT: 1.00 TC: 0.90 (0.66–1.22); age, sex, smoking status, and drinking status
CC: 1.48 (0.68–3.25);
TC + CC: 0.94 (0.70–1.26)
OSCC TT: 1.00 TC: 0.86 (0.58–1.26);
CC: 1.03 (0.36–2.97);
TC + CC: 0.87 (0.60–1.27)
LSCC TT: 1.00 TC: 1.02 (0.63–1.64);
CC: 1.62 (0.54–4.88);
TC + CC: 1.07 (0.67–1.69)
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were reported; (3) full-text were obtainable; (4) if 2 or
more studies covered the same population, we in-
cluded the study that contained most comprehensive
information; (5) the published language is English or
Chinese.
Search strategy
We searched PubMed, Embase, and Web of Science up
to January 20, 2015 (last updated on May 12, 2016)
using the following search terms: head and neck, oral,
oral cavity, pharyngeal, oropharynx, laryngeal, laryngo-
pharyngeal, mouth, tongue, carcinoma, cancer, tumour,
neoplasm, cyclooxygenase-2, COX-2, PTGs2, poly-
morphism, mutation, variant, and variation. We also
screened reference lists of recent reviews, eligible stud-
ies, and published meta-analyses on related topics for
additional eligible studies.
Data extraction
The following data were extracted from all eligible
studies by 2 authors independently and disagreements
(κ = 0.96) were resolved by discussion: last name of
the first author; publication year; country and ethni-
city; genotyping method; source of control, number
and genotyping distribution of cases and controls;
adjusted OR and its 95 % CI; adjusted variables; and
Hardy–Weinberg Equilibrium (HWE) for controls
[25]. The meta-analysis reviewers were blind to the
study author and institution of the studies undergoing
review.
Statistical analysis
The heterogeneity was assessed first using the Cochrane
Q and I2 statistic [26]. The heterogeneity was considered
acceptable if both p > 0.1 and I2 < 40 % and used the
fixed effect model, otherwise the random effect model
was used. For crude data, we used OR and its 95 %
confidence interval (CI) to quantify the strength of
association using the allele comparison, homozygote
comparison, heterozygote comparison, dominant model,
and recessive model genetic models. For adjusted
data, we directly combined the relevant ORs and their
95 % CIs according to reported genetic models. We
performed subgroup analyses based on ethnicity, site
of cancer, and HWE status for controls. The sensitiv-
ity analysis was performed by switching the effect
model. Publication bias was assessed by funnel plots
if the number of included studies was more than 9.
All statistical analyses were performed using Review
Manager (RevMan) software (version 5.2 for Windows;
Copenhagen: The Nordic Cochrane Centre, The Cochrane
Collaboration).
Table 2 Adjustment and adjusted data of included studies (Continued)
rs20417 (−765G > C)
Lin 2008 OSCC GG: 1.00 GC + CC: 0.22 (0.12–0.39) age, gender, ethnicity, educational level, and habits of betel
quid chewing, cigarette smoking, and alcohol drinking
Peters 2009 HNSCC GG: 1.00 GC: 0.99 (0.71–1.40); age (continuous), sex, smoking (continuous, 5 levels), and
alcohol consumption (continuous, 3 levels)
CC: 0.59 (0.23–1.49)
Mittal 2010 OSCC GG: 1.00 GC: 0.71 (0.42–1.18); age, gender
CC: 0.44 (0.13–1.46)
G: 1.00 C: 0.73 (0.50–1.08)
OSCC oral squamous cell carcinoma; HNSCC head and neck squamous cell carcinoma; LSCC laryngeal squamous cell carcinoma; OR odds ratio; CI confidence interval
Fig. 2 Forest plot for A vs. G model of crude data of rs689466 polymorphism
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Table 3 Overall and subgroups meta-analysis of COX-2 rs689466 polymorphism and HNSCC risk
Overall and subgroups No. OR (95 % CI) Heterogeneity (I2%/p)
A vs. G (unadjusted and adjusted)
Overall (unadjusted) 5 1.08 (0.97–1.09) 7 %/0.37
Overall (adjusted) 2 1.07 (0.84–1.36) 0 %/0.88
Asians (unadjusted) 4 1.12 (1.00–1.25) 0 %/0.56
Asians (adjusted) 2 1.07 (0.84–1.36) 0 %/0.88
Caucasian (unadjusted) 1 0.92 (0.73–1.16) NA
OSCC (unadjusted) 3 1.01 (0.87–1.16) 80 %/0.008
OSCC (adjusted) 1 1.03 (0.60–1.42) NA
LSCC (unadjusted) 1 0.96 (0.72–1.32) NA
AA vs. GG (unadjusted)
Overall 5 1.26 (1.01–1.57) 0 %/0.46
Asians 4 1.25 (0.99–1.57) 14 %/0.32
Caucasian 1 1.39 (0.70–2.73) NA
OSCC 3 1.07 (0.40–2.86) 86 %/<0.05
LSCC 1 1.30 (0.69–2.45) NA
AA vs. GA (unadjusted and adjusted)
Overall (unadjusted) 5 1.21 (1.01–1.45) 28 %/0.23
Overall (adjusted) 4 0.84 (0.69–1.03) 0 %/0.41
Asians (unadjusted) 4 1.17 (0.97–1.42) 30 %/0.23
Asians (adjusted) 3 0.89 (0.68–1.16) 23 %/0.27
Caucasian (unadjusted) 1 1.78 (0.89–3.57) NA
Caucasian (adjusted) 1 0.79 (0.58–1.07) NA
OSCC (unadjusted) 3 0.88 (0.53–1.48) 76 %/0.01
OSCC (adjusted) 2 1.23 (0.23–4.70) 67 %/0.08
LSCC (unadjusted) 1 1.17 (0.71–1.93) NA
LSCC (adjusted) 1 1.16 (0.65–2.09) NA
AA vs. GG + GA (unadjusted)
Overall 5 1.20 (1.01–1.43) 12 %/0.34
Asians 4 1.18 (0.99–1.41) 26 %/0.26
Caucasian 1 1.52 (0.78–2.96) NA
OSCC 3 0.89 (0.50–1.58) 83 %/0.003
LSCC 1 1.21 (0.75–1.94) NA
AA + GA vs. GG (unadjusted and adjusted)
Overall (unadjusted) 5 0.98 (0.84–1.15) 28 %/0.23
Overall (adjusted) 2 0.93 (0.72–1.21) 0 %/0.84
Asians (unadjusted) 4 1.07 (0.88–1.29) 13 %/0.33
Asians (adjusted) 2 0.93 (0.72–1.21) 0 %/0.84
Caucasian 1 0.83 (0.63–1.09) NA
OSCC (unadjusted) 3 1.03 (0.57–1.88) 75 %/0.02
OSCC (adjusted) 1 0.78 (0.53–1.14) NA
LSCC (unadjusted) 1 1.17 (0.68–2.03) NA
LSCC (adjusted) 1 1.23 (0.71–2.15) NA
OSCC oral squamous cell carcinoma; HNSCC head and neck squamous cell carcinoma; LSCC laryngeal squamous cell carcinoma; OR odds ratio; CI confidence
interval; NA not available
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Results
Study identification and characteristics
We yielded 408 papers initially and 8 case–control stud-
ies [27–34] were included finally, Fig. 1 showed the pro-
gress of study selection. Of them, 5 case–control studies
involving 1564 cases and 2346 controls focused on
COX-2 rs689466 polymorphism [28, 30, 31, 33, 34], 4
studies involving 1259 cases and 2097 controls on
COX-2 rs5275 polymorphism [27, 31, 33, 34], and 5
studies involving 1229 cases and 1164 controls on
COX-2 rs20417 polymorphism [28–32]. One study
did not satisfy the HWE for COX-2 rs5275 poly-
morphism [31] 1 for COX-2 rs20417 polymorphism
[32]. The main characteristics are shown in Table 1
and Table 2.
COX-2 rs689466 polymorphism and HNSCC risk
The pooled results from crude data indicated there
was a significant increased risk of association between
COX-2 rs689466 polymorphism and HNSCC risk in
AA vs. GG, AA vs. GA, and AA vs. GG + GA genetic
models while no association in A vs. G (Fig. 2) and
AA + GA vs. GG genetic models. Subgroup analyses
stratified by ethnicity and cancer site all revealed
negative results. The results of adjusted data showed
no association between COX-2 rs689466 polymorph-
ism and HNSCC risk in overall population and sub-
group analyses. The sensitivity analysis showed the
results without substantive change. Table 3 showed
the results of all analyses.
COX-2 rs5275 polymorphism and HNSCC risk
The pooled results of crude and adjusted data all showed
nonsignificant association between COX-2 rs5275 poly-
morphism and HNSCC risk in overall population, Fig. 3
showed the result of C vs. T model of crude data. The
results of subgroup analyses all revealed negative associ-
ation. The sensitivity analysis showed the results without
substantive change. Table 4 showed the results of all
analyses.
COX-2 rs20417 polymorphism and HNSCC risk
Table 5 presented the results of COX-2 rs20417 poly-
morphism and HNSCC risk. All results from unadjusted
data and adjusted data presented nonsignificant associ-
ation, either in overall or subgroups population; Fig. 4
showed the result of C vs. G model of crude data. The
sensitivity analysis showed the results without substan-
tive change.
Publication bias
Due to the limited number of included studies, we did
not conduct publication bias analysis.
Discussion
The rs20417, rs689466, and rs5275 polymorphisms
are the three commonly investigated polymorphisms
in the COX-2 gene [14, 15]. In 2007, Campa D et al.
conducted a case–control study including 533 cases
and 1066 controls which indicated no significant asso-
ciation between COX-2 rs5275 polymorphism and
HNSCC risk [27]. Then Chiang SL et al., in 2008,
showed that COX-2 rs20417 polymorphism was not
associated with OSCC risk but COX-2 rs689466 was
associated with increased risk of OSCC [28]. However,
another study obtained this increased risk between
COX-2 rs20417 polymorphism and OSCC [29]. Simi-
larly, published studies on these three polymorphisms
revealed inconsistent results. This meta-analysis based
on the crude data indicated there might be an associ-
ation with increased risk of HNSCC in COX-2
rs689466 polymorphism, but identified negative asso-
ciation between COX-2 rs5275 and COX-2 rs20417
polymorphisms and HNSCC risk. However, the com-
bined results of adjusted data all yielded nonsignifi-
cant associations between these three polymorphisms
and HNSCC risk. The subgroup analyses according to
ethnicity and sites of HNSCC confirm this negative
association.
This meta-analysis is the first study to investigate these
three polymorphisms and risk of HNSCC. Unlike the
Fig. 3 Forest plot for C vs. T model of crude data of rs5275 polymorphism
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Table 4 Overall and subgroups meta-analysis of COX-2 rs5275 polymorphism and HNSCC risk
Overall and subgroups No. OR (95 % CI) Heterogeneity (I2%/p)
C vs. T (unadjusted and adjusted)
Overall (unadjusted) 4 0.92 (0.81–1.04) 1 %/0.38
Overall (adjusted) 2 1.06 (0.81–1.40) 0 %/0.33
HWE (Yes–unadjusted) 3 0.94 (0.82–1.06) 0 %/0.45
HWE (No–unadjusted) 1 0.69 (0.42–1.11) NA
Asians (unadjusted) 3 0.97 (0.87–1.16) 17 %/0.30
Asians (adjusted) 2 1.06 (0.81–1.40) 0 %/0.33
Caucasian (unadjusted) 1 0.87 (0.74–1.04) NA
OSCC (unadjusted) 3 0.90 (0.76–1.06) 0 %/0.52
OSCC (adjusted) 1 0.88 (0.55–1.40) NA
LSCC (unadjusted) 2 0.88 (0.73–1.06) 47 %/0.17
CC vs. TT (unadjusted and adjusted)
Overall (unadjusted) 4 0.92 (0.67–1.27) 36 %/0.19
Overall (adjusted) 4 0.92 (0.67–1.27) 49 %/0.12
HWE (Yes–unadjusted) 3 0.89 (0.64–1.24) 47 %/0.15
HWE (No–unadjusted) 1 2.59 (0.31–21.82) NA
Asians (unadjusted) 3 1.49 (0.87–2.57) 0 %/0.86
Asians (adjusted) 3 1.45 (0.81–2.59) 16 %/0.30
Caucasian (unadjusted) 1 0.71 (0.47–1.07) NA
Caucasian (adjusted) 1 0.75 (0.51–1.10) NA
OSCC (unadjusted) 3 0.92 (0.59–1.43) 0 %/0.48
OSCC (adjusted) 3 0.89 (0.56–1.40) 0 %/0.57
LSCC (unadjusted) 2 0.98 (0.35–2.75) 67 %/0.08
LSCC (adjusted) 2 0.88 (0.34–2.26) 60 %/0.12
CC vs. CT (unadjusted and adjusted)
Overall (unadjusted) 4 1.02 (0.74–1.41) 48 %/0.12
Overall (adjusted) 4 0.99 (0.84–1.16) 0 %/0.60
HWE (Yes–unadjusted) 3 0.96 (0.68–1.33) 42 %/0.18
HWE (No–unadjusted) 1 5.13 (0.61–42.88) NA
Asians (unadjusted) 3 1.73 (0.99–3.01) 0 %/0.54
Asians (adjusted) 3 0.93 (0.73–1.19) 0 %/0.49
Caucasian (unadjusted) 1 0.77 (0.52–1.16) NA
Caucasian (adjusted) 1 1.03 (0.82–1.28) NA
OSCC (unadjusted) 3 0.99 (0.64–1.53) 44 %/0.17
OSCC (adjusted) 3 1.02 (0.80–1.30) 28 %/0.25
LSCC (unadjusted) 2 0.87 (0.54–1.40) 50 %/0.16
LSCC (adjusted) 2 0.92 (0.70–1.21) 0 %/0.62
CC vs. CT + TT (unadjusted)
Overall 4 0.96 (0.70–1.31) 43 %/0.15
HWE (Yes) 3 0.91 (0.66–1.25) 46 %/0.16
HWE (No) 1 3.65 (0.45–29.89) NA
Asians 3 1.58 (0.93–2.71) 0 %/0.70
Caucasian 1 0.74 (0.50–1.09) NA
OSCC 3 0.94 (0.62–1.43) 16 %/0.30
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usual method, based on unadjusted data [7, 8, 13, 14, 35–
38], we also extracted the adjusted data and pooled
them for investigating the interactions between gen-
etic polymorphisms and environmental risk factors.
Interestingly, the unadjusted data showed COX-2
rs689466 polymorphism might play a role in in-
creased risk while the adjusted data showed a nega-
tive association. As we know, smoking and alcohol
are the well known risk factors for HNSCC [2, 4].
One study by Mittal M et al. [31] adjusted age and
gender only, while the other included studies all ad-
justed smoking and alcohol. While, there is a relevant
meta-analysis by Zhao F et al. published in 2014 [39].
This meta-analysis focused on the association between
COX-2 rs20417 polymorphism and digestive system
cancer, including three studies of HNSCC [28, 29, 31]
and revealed negative association based on the perform-
ance of 2 genetic models (GG + GC vs. GG: OR = 0.66,
95 % CI = 0.29, 1.50; C vs. G: OR = 0.95, 95 % CI = 0.56,
1.63). Whereas, our meta-analysis performed all recom-
mended 5 genetic models, included more studies, and
considered adjusted data. Furthermore, our meta-
analysis investigated 3 polymorphisms at the same time
and only focussed on HNSCC. Different cancers have
their own histological characteristics and of course their
own predisposing genes. The identical polymorphism in
the same gene, different polymorphisms in the same
gene, and identical polymorphism in different genes
might reveal different associations in different cancers.
Hence, our meta-analysis was more useful for reference.
Also considering this point, we extracted the data for
OSCC and LSCC if applicable. The results of all genetic
models all showed negative association of OSSS, LSCC,
and overall population. In addition we considered
genetic background. We stratified the population by
ethnicity to explore whether different ethnicities have
different susceptibility. The results showed all these 3
polymorphisms in COX-2 gene regardless of genetic
background of HNSCC.
As we know, COX-2 participated in cell prolifera-
tion and tumour microenvironment and associated
with many types of cancer. However, our results
showed there was non-association of COX-2 and
HNSCC. The possible mechanism of the negative re-
sult due to the relative small sample size, which is
not enough to detect the small genetic effect. More-
over, COX-2 gene polymorphisms were really not as-
sociated with HNSCC risk. Third, the compromise
effect might be existed in the 3 polymorphisms of
COX-2 or other environmental risk factors, such as
green tea. Besides, the haplotype analysis was not per-
formed because of limited information of included
studies. However, to explore the true effects and pos-
sible mechanism between them remain necessary.
Heterogeneity is 1 of the important issues in genetic
association meta-analysis. This limitation also existed
in the present meta-analysis, some genetic models
showed clear homogeneity while some showed hetero-
geneity, either in overall population or subgroup ana-
lyses (Tables 3, 4 and 5). The heterogeneity might be
originated from different genotyping methods, envir-
onmental differences, or different lifestyles. However,
we could not explore these factors due to the lack of
individual data. Also, the number of eligible studies
and sample sizes of for each polymorphism was insuf-
ficient. Statistical power is influenced by small sample
sizes so owing to this limitation, we could not per-
form publication bias of any polymorphism. We did
Table 4 Overall and subgroups meta-analysis of COX-2 rs5275 polymorphism and HNSCC risk (Continued)
LSCC 2 1.02 (0.40–2.60) 63 %/0.10
CC + CT vs. TT (unadjusted and adjusted)
Overall (unadjusted) 4 0.90 (0.77–1.04) 0 %/0.41
Overall (adjusted) 3 0.98 (0.84–1.15) 0 %/0.78
HWE (Yes–unadjusted) 3 0.92 (0.79–1.08) 0 %/0.74
HWE (No–unadjusted) 1 0.57 (0.30–1.05) NA
Asians (unadjusted) 3 0.91 (0.74–1.12) 29 %/0.25
Asians (adjusted) 2 1.00 (0.79–1.27) 0 %/0.49
Caucasian (unadjusted) 1 0.88 (0.70–1.10) NA
Caucasian (adjusted) 1 0.97 (0.78–1.20) NA
OSCC (unadjusted) 3 1.09 (0.55–2.16) 91 %/<0.05
OSCC (adjusted) 2 1.01 (0.80–1.27) 2 %/0.31
LSCC (unadjusted) 2 0.87 (0.68–1.10) 7 %/0.30
LSCC (adjusted) 2 0.89 (0.69–1.15) 0 %/0.35
OSCC oral squamous cell carcinoma; HNSCC head and neck squamous cell carcinoma; LSCC laryngeal squamous cell carcinoma; OR odds ratio; CI confidence
interval; NA not available; HWE Hardy–Weinberg Equilibrium
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Table 5 Overall and subgroups meta-analysis of COX-2 rs20417 polymorphism and HNSCC risk
Overall and subgroups No. OR (95 % CI) Heterogeneity (I2%/p)
C vs. G (unadjusted and adjusted)
Overall (unadjusted) 5 1.13 (0.62–2.05) 92 %/<0.10
OSCC (unadjusted) 4 1.22 (0.52–2.89) 94 %/<0.10
OSCC (adjusted) 1 0.73 (0.50–1.08) NA
Asians (unadjusted) 4 1.22 (0.52–2.89) 94 %/<0.10
Caucasian (unadjusted) 1 0.92 (0.70–1.21) NA
HWE (Yes–unadjusted) 4 0.78 (0.52–1.18) 83 %/<0.10
HWE (No–unadjusted) 1 6.08 (3.03–12.22) NA
CC vs. GG (unadjusted and adjusted)
Overall (unadjusted) 5 1.17 (0.25–5.46) 80 %/<0.10
Overall (adjusted) 2 0.53 (0.25–1.11) 0 %/0.71
OSCC (unadjusted) 4 1.79 (0.10–31.00) 89 %/<0.10
OSCC (adjusted) 1 0.44 (0.13–1.46) NA
Asians (unadjusted) 4 1.79 (0.10–31.00) 89 %/<0.10
Caucasian (unadjusted) 1 0.62 (0.25–1.50) NA
HWE (Yes–unadjusted) 4 0.55 (0.27–1.13) 0 %/0.67
HWE (No–unadjusted) 1 7.75 (1.70–35.33) NA
GC vs. GG (unadjusted and adjusted)
Overall (unadjusted) 5 0.69 (0.36–1.35) 0 %/0.75
Overall (adjusted) 2 0.90 (0.68–1.19) 9 %/0.29
OSCC (unadjusted) 4 0.80 (0.30–2.09) 0 %/0.50
OSCC (adjusted) 1 0.71 (0.42–1.18) NA
Asians (unadjusted) 4 0.80 (0.30–2.09) 0 %/0.50
Caucasian (unadjusted) 1 0.62 (0.24–1.55) NA
HWE (Yes–unadjusted) 4 0.62 (0.30–1.29) 0 %/0.98
HWE (No–unadjusted) 1 1.29 (0.23–7.31) NA
CC vs. CG + GG (unadjusted)
Overall 5 1.15 (0.29–4.54) 76 %/0.02
OSCC 4 1.76 (0.15–21.30) 85 %/<0.10
Asians 4 1.76 (0.15–21.30) 85 %/<0.10
Caucasian 1 0.62 (0.25–1.50) NA
HWE (Yes) 4 0.58 (0.29–1.18) 0 %/0.84
HWE (No) 1 6.43 (1.41–29.27) NA
CC + CG vs. GG (unadjusted and adjusted)
Overall (unadjusted) 5 1.07 (0.51–2.24) 93 %/<0.10
OSCC (unadjusted) 4 1.13 (0.39–3.26) 95 %/<0.10
OSCC (adjusted) 1 0.22 (0.12–0.39) NA
Asians (unadjusted) 4 1.13 (0.39–3.26) 95 %/<0.10
Caucasian (unadjusted) 1 0.90 (0.70–1.30) NA
HWE (Yes–unadjusted) 4 0.72 (0.39–1.33) 90 %/<0.10
HWE (No–unadjusted) 1 6.45 (2.90–14.35) NA
OSCC oral squamous cell carcinoma; HNSCC head and neck squamous cell carcinoma; LSCC laryngeal squamous cell carcinoma; OR odds ratio; CI confidence
interval; NA not available; HWE Hardy–Weinberg Equilibrium
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not confirm whether relevant publications published
in languages other than English or Chinese existed,
due to lack of right to search and ability to read, as
such we may have missed some eligible studies. This
limitation was also revealed in the included population.
Our meta-analysis only included Asians and Caucasians,
hence, our results had no value for other ethnicities. Fi-
nally, lacking a relevant recommended tool, we could not
assess the methodological quality of included studies and
did not performed subgroup analysis based on high vs.
low quality. As such, we did not conduct the meta-
regression of methodological quality.
Conclusion
In summary, our meta-analysis based on crude and ad-
justed data showed that none of COX-2 rs689466,
rs5275, and rs20417 polymorphisms was associated with
risk of HNSCC. Due to limitations of our meta-analysis,
such as insufficient sample sizes, our results should be
treated with caution. We recommend further high qual-
ity studies, with large sample sizes and stratified by
smoking status and alcohol consumption, be conducted
to provide high level evidence for clinical implication.
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